The FDA accepted a new drug application for suzetrigine, a non-opioid analgesic, based on the results from clinical trials in patients with neuropathy and those post-surgery.
Celebrating its long history, the Division of Rheumatology & Immunology at Medical University of South Carolina has made strides in scleroderma, lupus and more.
As the Asia-Pacific League of Associations for Rheumatology (APLAR) convened its 26th annual congress in Singapore this August, Ellen M. Gravallese, MD, was honored as an APLAR Master. Dr. Gravallese is currently the Theodore Bevier Bayles Professor of Medicine at Harvard Medical School, Boston, chief of the Division of Rheumatology, Inflammation and Immunity at Brigham…
Ethical conduct is the cornerstone of any professional organization, particularly when its decisions have an impact on public health. The ACR recognizes the importance of upholding ethical standards and has established a Code of Ethics to guide its members. Here we explore the practical application of the ACR’s Code of Ethics.1 Manage Potential Conflicts Central…
Autoimmune rheumatic diseases (AIRDs) are known for their systemic presentations and multi-organ involvement. Numerous infectious diseases, particularly mycobacterial, fungal and indolent bacterial infections endemic to specific geographic regions, present with varied signs and symptoms of multi-system involvement and can mimic AIRDs. Thus, differentiating infection from an AIRD is critical to resolve competing treatment approaches. This…
Renal osteodystrophy is associated with chronic kidney disease (CKD) and its associated metabolic derangements, most commonly CKD stages 3–5. It is often subclassified into four histological subtypes, with definite distinctions unable to be made clinically. These four subtypes, which may only be differentiated by bone biopsy, include: osteitis fibrosa cystica, mixed uremic osteodystrophy, osteomalacia and…
Kamini E. Kuchinad, MD, MPH, Ambereen Mehta, MD, MPH, David Wu, MD, & Jemima Albayda, MD |
“Our patients’ goals for their care aren’t always the same as ours. We’re typically focused on disease control, and they’re often focused on quality of life. Having ongoing discussions about care goals is the only way to know when it’s time to switch gears. Would you know when to refer your patients to palliative care?…
Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.